In a 11-min video, five experts in addiction explain why KT-110 is a game changer and why it is a hope for millions of AUD patients. Henri-Jean Aubin is Professor of Psychiatry and Addictology at Hôpital Pitié-Salpétrière in Paris,
Kinnov Therapeutics was present at the 37th ECNP Congress
Kinnov Therapeutics was present at the 37th ECNP congress https://www.ecnp.eu/congress2024/ECNPcongress, in Milan 21-24 Sep, 2024. Within the scope of ECNP’s New Medications Symposium, Prof Henri-Jean Aubin and Julien Guiraud were invited to present results of phase 2 clinical trials. The
Our phase II results published in Addiction journal !
We are thrilled to announce our ground breaking Phase II results published in Addiction Journal (April 10th 2024) entitled: Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial. https://onlinelibrary.wiley.com/doi/10.1111/add.16484 The article demonstrates
New galenic form accepted for evaluation on patients
Kinnov Therapeutics received the authorization to test KT-110 for clinical pharmacokinetics of once daily on 8 subjects in France.
ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) is the french Drug Regulatory Authority.
Outsourcing-Pharma shares article providing insights as to why KT-110 is fresh hope for heavy drinkers
Through review of Kinnov phase 2 trial results, and interview with Henri-Jean Aubin, Alain Puech and Emmanuel de Rivoire, Outsourcing-Pharma shares an article providing key answers as to why people affected with AUD could see their alcohol intake reduced by
European Commission shares results of Kinnov projects funded by their Horizon 2020 grant
CORDIS platform shares results of Kinnov projects funded by European Commission within the scope of the Horizon 2020 program: https://cordis.europa.eu/project/id/873252/reporting/fr CORDIS is the main source of results of European Commission’s innovation and research funding programs. Horizon 2020 is the funding
Kinnov Therapeutics will be present at the 29th annual BIO-Europe
Kinnov Therapeutics will be present at the 29th annual BIO-Europe congress BIO-Europe | Meet dealmakers from biotech, pharma and finance (informaconnect.com), in Munich on November 6, 7 and 8, 2023.
Alcohol dependency: in a phase 2 clinical trial, a combination of drugs gave a better results than current medications [article in French]…
![Alcohol dependency: in a phase 2 clinical trial, a combination of drugs gave a better results than current medications [article in French]…](https://www.kinnov-therapeutics.com/wp-content/uploads/2023/10/Alcohol-dependency-in-a-phase-2-clinical-trial-a-combination-of-drugs-gave-a-better-results-than-current-medications-article-in-French…-750x350.jpg "Alcohol dependency: in a phase 2 clinical trial, a combination of drugs gave a better results than current medications [article in French]…")
A phase 2 trial based on the simultaneous blockade of two neurobiological pathways has shown exciting results in patients with severe alcohol use disorder. Actualités Medscape, 23 juin 2022
Alcooldépendance : dans un essai de phase 2, une combinaison fait mieux que les médicaments actuels
Un essai de phase 2 reposant sur le blocage simultané de deux voies neurobiologiques a obtenu des résultats enthousiasmants chez des patients atteints d’un trouble sévère de l’usage de l’alcool. Actualités Medscape, 23 juin 2022
Kinnov Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder
Kinnov-Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder. Kinnov-Therapeutics has reached a key clinical milestone for treatment of Alcohol Use Disorder with a Phase 2 clinical study for its game changing drug